Nonlinear Pharmacokinetics: Causes of Nonlinearity

Nonlinear drug absorption occurs when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of presystemic metabolism in the gut wall or liver. For example, high doses of propranolol saturate presystemic metabolism, resulting in increased bioavailability. This means small dose changes can produce large variations in plasma concentration.

Nonlinear distribution arises when binding sites on plasma proteins or tissues become saturated at high drug concentrations. Phenylbutazone exemplifies this: at high concentrations, it saturates plasma protein binding sites, increasing the unbound drug fraction. This pharmacologically active unbound fraction can enhance therapeutic effects or cause potential toxicity.

Enzyme autoinduction occurs when repetitive drug administration induces its own metabolism, decreasing peak plasma concentration over time. Carbamazepine demonstrates this phenomenon: repeated doses stimulate enzyme activity, reducing drug levels and potentially affecting efficacy. This nonlinear metabolic process requires dose adjustments to maintain therapeutic effectiveness.

Nonlinear renal excretion occurs when tubular carrier systems become saturated, reducing the reabsorption of substances like glucose and water-soluble vitamins. When transporters reach saturation capacity, renal clearance of these substances increases. This saturation-dependent mechanism creates dose-dependent changes in drug elimination rates.

Pathological changes such as renal nephrotoxicity from aminoglycosides directly alter renal drug excretion, causing nonlinear kinetics. Kidney damage impairs the elimination of drugs primarily excreted by the kidneys, leading to drug accumulation and potential toxicity. These pathological effects demonstrate how organ dysfunction disrupts normal pharmacokinetic processes.

Capacity-limited metabolism occurs when enzyme saturation limits the rate of drug metabolism at high concentrations, following Michaelis-Menten kinetics. Enzyme induction, conversely, increases enzyme production through repeated drug exposure, enhancing metabolic capacity. Both mechanisms cause nonlinearity but through opposite effects: saturation decreases clearance while induction increases it.

Carrier-mediated transport systems exhibit saturation kinetics, meaning their transport capacity is limited. When drug concentration exceeds the transporter's capacity, absorption becomes rate-limited, creating nonlinear dose-concentration relationships. This saturable transport mechanism contrasts with passive diffusion and explains why some drugs show disproportionate plasma concentration increases at higher doses.